GB1107 |
Catalog No.GC18279 |
GB1107 es un inhibidor potente, selectivo y activo por vÍa oral de la galectina-3 (Gal-3) con una Kd de 37 nM para la galectina-3 humana. GB1107 reduce el crecimiento de adenocarcinoma de pulmÓn humano y de ratÓn y bloquea la metÁstasis en el modelo singénico.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1978336-61-6
Sample solution is provided at 25 µL, 10mM.
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model[1].
Treatment with GB1107 (0-1 μM) increases tumor M1 macrophage polarization and CD8+ T cell infiltration in LLC cells by flow cytometric analysis. GB1107 potentiates the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules[1].
GB1107 (10 mg/kg, p.o., once daily from day 18-30 post implantation) treatment results in significantly reduced tumor growth and final tumor weights[1].
Reference:
[1]. Vuong L, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res. 2019 Jan 23. pii: canres.2244.2018.
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *